Luciano Costa, MD, PhD, Discusses the Rationale for Examining Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Video

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the decision to start the phase 2 MASTER trial for multiple myeloma.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Luciano Costa, MD, PhD, of O’Neal Comprehensive Cancer Center, about the rationale for the phase 2 MASTER trial (NCT03224507), which examined daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma. Additionally, investigators examined how minimal residual disease may be used to tailor treatment with this regimen. 

Transcript:

The [MASTER] study came about due to the recognition that patients with multiple myeloma can have a very heterogeneous disease that responds very differently to therapy, and some patients have outstanding response that can last many years. Some patients have a very short duration of response, regardless of what you do. Also, patients tend to achieve different levels of response at different time points. However, the treatments have been developed in clinical trials where every patient in a certain arm gets the same treatment.

The attempt here was to take a very powerful 4 drug combination leveraging the best and most established classes of therapy in myeloma [that were] combined safely to achieve a deep response [and] utilizing transplant given its known benefit in deepening responses in most patients. [From there, therapy can be] tailored to the achievement of [minimal residual disease] (MRD) negativity, not only at a single point, but also confirming at least 2 consecutive points. As a consequence, some patients need very brief therapy, and some patients need longer therapy. We also explored the possibility of [withholding maintenance therapy in] those patients who have confirmed MRD-negative responses, coming from the perspective that the role of maintenance therapy although well-established, was well established at a time when regimens did not lead to frequent, deep responses. Those patients could do very well with omission of therapy, alleviating the financial and physical burden of continuous therapy and, in exchange, monitoring disease using this very sensitive techniques that we have with MRD.

Reference

Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed multiple myeloma (NDMM). Paper presented at: 18th International Myeloma Workshop; September 8-11, 2021; Vienna, Austria. Accessed September 11, 2021.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content